FI942622A - Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi - Google Patents

Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi Download PDF

Info

Publication number
FI942622A
FI942622A FI942622A FI942622A FI942622A FI 942622 A FI942622 A FI 942622A FI 942622 A FI942622 A FI 942622A FI 942622 A FI942622 A FI 942622A FI 942622 A FI942622 A FI 942622A
Authority
FI
Finland
Prior art keywords
growth factor
fibrosis
extracellular matrix
transforming growth
factor beta
Prior art date
Application number
FI942622A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI942622A0 (fi
Inventor
Erkki I Ruoslahti
Wayne A Border
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Publication of FI942622A0 publication Critical patent/FI942622A0/fi
Publication of FI942622A publication Critical patent/FI942622A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
FI942622A 1991-12-04 1994-06-03 Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi FI942622A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80328591A 1991-12-04 1991-12-04
PCT/US1992/010550 WO1993010808A1 (fr) 1991-12-04 1992-12-04 INHIBITION DU FACTEUR DE CROISSANCE TRANSFORMATEUR β AFIN DE PREVENIR L'ACCUMULATION DE LA MATRICE EXTRACELLULAIRE

Publications (2)

Publication Number Publication Date
FI942622A0 FI942622A0 (fi) 1994-06-03
FI942622A true FI942622A (fi) 1994-07-27

Family

ID=25186123

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942622A FI942622A (fi) 1991-12-04 1994-06-03 Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi

Country Status (10)

Country Link
EP (1) EP0616536B1 (fr)
JP (2) JP3854307B2 (fr)
AT (1) ATE177644T1 (fr)
AU (2) AU670770B2 (fr)
CA (1) CA2124591A1 (fr)
DE (1) DE69228700T2 (fr)
DK (1) DK0616536T3 (fr)
FI (1) FI942622A (fr)
NO (1) NO942072L (fr)
WO (1) WO1993010808A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
ATE315939T1 (de) * 1993-11-19 2006-02-15 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
EP0754058B1 (fr) * 1994-03-29 1999-11-03 The Victoria University Of Manchester Cicatrisation
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
AU1826799A (en) * 1998-01-09 1999-07-26 University Of Utah, The Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by tgfbeta using renin inhibitors
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
EP1140041A2 (fr) * 1999-01-05 2001-10-10 University of Utah Research Foundation Procedes de traitement d'etats associes a l'accumulation d'un excedent de matrice extracellulaire
US6864236B1 (en) 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
DE60230877D1 (de) 2001-08-15 2009-03-05 Univ Brown Res Found Behandlung von muskeldystrophien und verwandter erkrankungen
JP4564261B2 (ja) * 2002-01-22 2010-10-20 ジェンザイム、コーポレーション 慢性的移植片拒絶反応の治療と予防のためのＴＧＦ−β拮抗薬の使用
WO2004075917A1 (fr) * 2003-02-28 2004-09-10 Toudai Tlo, Ltd. Inhibiteur de fibrose d'organe ou de tissu
EP1948675B1 (fr) 2005-10-25 2014-07-30 The Johns Hopkins University Methodes et compositions de traitement du syndrome de marfan et de troubles associes
EP2230252A1 (fr) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation de la thromborésistance endothéliale
EP1983345A1 (fr) * 2007-04-17 2008-10-22 Roche Diagnostics GmbH Moyen et procédé pour l'évaluation du risque d'une intervention cardiaque chez des patients souffrant d'une maladie cardiaque coronarienne stable basés sur le GDF-15
HUE027831T2 (en) 2010-03-12 2016-11-28 Genzyme Corp Combination therapy for breast cancer
ES2691443T3 (es) 2010-05-17 2018-11-27 Brown University Mutantes de biglicano y agentes terapéuticos relacionados y métodos de uso
WO2012092299A1 (fr) 2010-12-27 2012-07-05 Brown University Méthodes thérapeutiques et diagnostiques impliquant le biglycane et l'utrophine
CA2823154A1 (fr) 2010-12-27 2012-07-05 Lsip, Llc Cellules spi et leur procede de production
KR102051014B1 (ko) 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
EP2799537B1 (fr) 2011-12-28 2021-09-22 Kyoto Prefectural Public University Corporation Normalisation d'une culture de cellules endothéliales de la cornée
EP3064222B1 (fr) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Médicament thérapeutique contenant un inhibiteur de tgf-beta signal pour des maladies associées à la mort cellulaire du réticulum endoplasmique dans l'endothélium de la cornée
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2017223268A1 (fr) * 2016-06-22 2017-12-28 Yale University Compositions et procédés de resensibilisation de cellules à des inhibiteurs des protéines de bromodomaine et de domaine extraterminal (beti)
JP7109039B2 (ja) 2016-07-07 2022-07-29 国立大学法人千葉大学 抗線維症剤およびリン酸化Ｓｍａｄ核内移行阻害剤
WO2019143219A1 (fr) * 2018-01-22 2019-07-25 고려대학교 산학협력단 Composition pharmaceutique pour la prévention ou le traitement du diabète, contenant du biglycane en tant que principe actif
KR102141125B1 (ko) * 2018-01-22 2020-08-05 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
US20220160821A1 (en) * 2019-04-11 2022-05-26 Korea University Research And Business Foundation Pharmaceutical composition for preventing or treating obesity containing biglycan as active ingredient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004748A1 (fr) * 1989-09-29 1991-04-18 La Jolla Cancer Research Foundation INHIBITION DE FACTEUR β DE CROISSANCE A TRANSFORMATION AFIN D'EMPECHER L'ACCUMULATION DE MATRICE EXTRACELLULAIRE
WO1991010727A1 (fr) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibiteurs de facteurs regulateurs cellulaires

Also Published As

Publication number Publication date
CA2124591A1 (fr) 1993-06-10
AU3242993A (en) 1993-06-28
DE69228700D1 (de) 1999-04-22
JPH07504650A (ja) 1995-05-25
DE69228700T2 (de) 1999-09-09
JP3854307B2 (ja) 2006-12-06
WO1993010808A1 (fr) 1993-06-10
FI942622A0 (fi) 1994-06-03
AU7051896A (en) 1997-01-16
ATE177644T1 (de) 1999-04-15
NO942072D0 (no) 1994-06-03
EP0616536A1 (fr) 1994-09-28
JP2004043507A (ja) 2004-02-12
NO942072L (no) 1994-08-03
EP0616536B1 (fr) 1999-03-17
AU670770B2 (en) 1996-08-01
DK0616536T3 (da) 1999-10-11

Similar Documents

Publication Publication Date Title
FI942622A0 (fi) Transformoivan kasvutekijän beta inhibiitio solun ulkopuolisen matriisin akkumulaation estämiseksi
ATE193541T1 (de) Insulinotropes hormon
El-sherif et al. Quinidine-induced long QTU interval and torsade de pointes: role of bradycardia-dependent early afterdepolarizations
Loddick et al. Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke
DE60023492D1 (de) Glucagon antagonisten/inverse agonisten
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
EP1123129A4 (fr) Systemes et composes destines a l'administration de medicament dans des regions interstitielles du myocarde
OSBORNE et al. Receptor binding and processing of epidermal growth factor by human breast cancer cells
NO921119L (no) Inhibering av transformerende vekstfaktor beta for aa forhindre akkumulering av ekstracellulaer matriks
RU94013439A (ru) Гетероциклические соединения, способ их получения, фармацевтическая композиция и способ лечения
ES2054995T3 (es) Nuevos derivados del acido benzoico y acido fenilacetico, su obtencion y empleo como medicamentos.
IT8619684A0 (it) Preparato di acido ialuronico chimicamente modificato e metodo per recuperarlo da tessuti animali.
JPS6429308A (en) Treatment of hyperhydrosis, psoriasis and wrinkle
ATE410506T1 (de) Behandlung der pompeschen krankheit
DE60000288D1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
RU2738416C2 (ru) Длительно действующее производное адреномедуллина
Doi et al. Vascular endothelial growth factor suppresses C-type natriuretic peptide secretion
AR240926A2 (es) "procedimiento para la preparacion de 8-isopropil-6-dimetilamino metil-7-hidroxi-4-metil-cumarina".
Louis et al. A diabetogenic polypeptide from bovine adenohypophysis similar to that excreted in lipoatrophic diabetes
KR890006657A (ko) 6-클로로-4-하이드록시-2-메틸-N-(2-피리딜)-2H-티에노(2,3-e)-1,2- 티아진-3 -카복스아미드 1,1- 디옥사이드의 엔올에테르 이의 제조방법 및 이의 용도
Höllt et al. Increased biosynthesis of β-endorphin in the pars intermedia of rat pituitaries after long-term treatment with haloperidol
Weber et al. 32. Overexpression of ovine insulin-like growth factor-I in the mammary glands of transgenic mice
UA72871C2 (uk) Засіб для лікування та профілактики цукрового діабету та спосіб лікування
White Hormones of the Adenohypophysis
TH51594A (th) สารประกอบเปปไทด์-1 แอนาลอกคล้ายกับกลูคากอน

Legal Events

Date Code Title Description
FD Application lapsed